Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for economics of pharmaceutical IP
Does the economic impact of SPCs necessitate SPC Regulation reform? The European Commission wants to find out Does the economic impact of SPCs necessitate SPC Regulation reform? The European Commission wants to find out Reviewed by Annsley Merelle Ward on Thursday, January 19, 2017 Rating: 5
Letter from AmeriKat: Will narrowing innovator-generic price gap change IP law? Letter from AmeriKat: Will narrowing innovator-generic price gap change IP law? Reviewed by Annsley Merelle Ward on Monday, March 16, 2015 Rating: 5
Letter from AmeriKat: Brought to you by the Letters 'A', 'W' and 'R' and the numbers 50 million and $100 million Letter from AmeriKat: Brought to you by the Letters 'A', 'W' and 'R' and the numbers 50 million and $100 million Reviewed by Annsley Merelle Ward on Sunday, May 20, 2012 Rating: 5
Katonomics 6: the Economics of IP in Pharmaceuticals Katonomics 6: the Economics of IP in Pharmaceuticals Reviewed by Jeremy on Monday, December 12, 2011 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.